rs148921184
Variant summary
Our verdict is Uncertain significance. The variant received 2 ACMG points: 2P and 0B. PM1
The NM_006567.5(FARS2):c.1268G>A(p.Arg423Gln) variant causes a missense change. The variant allele was found at a frequency of 0.00011 in 1,614,052 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R423W) has been classified as Uncertain significance.
Frequency
Consequence
NM_006567.5 missense
Scores
Clinical Significance
Conservation
Publications
- metabolic diseaseInheritance: AR Classification: DEFINITIVE Submitted by: G2P
- combined oxidative phosphorylation defect type 14Inheritance: AR Classification: STRONG, MODERATE, SUPPORTIVE Submitted by: Orphanet, Ambry Genetics, Labcorp Genetics (formerly Invitae)
- hereditary spastic paraplegia 77Inheritance: AR Classification: STRONG, SUPPORTIVE, LIMITED Submitted by: Orphanet, Ambry Genetics, Labcorp Genetics (formerly Invitae)
- Leigh syndromeInheritance: AR Classification: MODERATE Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 2 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| FARS2 | ENST00000274680.9 | c.1268G>A | p.Arg423Gln | missense_variant | Exon 7 of 7 | 1 | NM_006567.5 | ENSP00000274680.4 | ||
| FARS2 | ENST00000324331.10 | c.1268G>A | p.Arg423Gln | missense_variant | Exon 7 of 7 | 1 | ENSP00000316335.5 | |||
| FARS2 | ENST00000648580.1 | n.1218-50367G>A | intron_variant | Intron 6 of 8 | ENSP00000497889.1 |
Frequencies
GnomAD3 genomes AF: 0.000145 AC: 22AN: 152182Hom.: 0 Cov.: 33 show subpopulations
GnomAD2 exomes AF: 0.0000677 AC: 17AN: 251270 AF XY: 0.0000442 show subpopulations
GnomAD4 exome AF: 0.000107 AC: 156AN: 1461752Hom.: 0 Cov.: 31 AF XY: 0.0000798 AC XY: 58AN XY: 727182 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.000144 AC: 22AN: 152300Hom.: 0 Cov.: 33 AF XY: 0.000107 AC XY: 8AN XY: 74480 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Combined oxidative phosphorylation defect type 14 Uncertain:3
This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 423 of the FARS2 protein (p.Arg423Gln). This variant is present in population databases (rs148921184, gnomAD 0.02%). This missense change has been observed in individual(s) with developmental delay, hypotonia, and speech delay (PMID: 28419689). ClinVar contains an entry for this variant (Variation ID: 214337). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt FARS2 protein function. Experimental studies have shown that this missense change affects FARS2 function (PMID: 28419689). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
- -
This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. -
not specified Uncertain:1
Variant summary: FARS2 c.1268G>A (p.Arg423Gln) results in a conservative amino acid change located in the Ferrodoxin-fold anticodon-binding domain (IPR005121) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 6.8e-05 in 251270 control chromosomes. c.1268G>A has been reported in the literature in individuals affected with developmental delay and hypotonia (Kartvelishvili_2017). This report does not provide unequivocal conclusions about association of the variant with FARS2-Related Disorders. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication have been ascertained in the context of this evaluation (PMID: 28419689). Five submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. -
Inborn genetic diseases Uncertain:1
The c.1268G>A (p.R423Q) alteration is located in exon 7 (coding exon 6) of the FARS2 gene. This alteration results from a G to A substitution at nucleotide position 1268, causing the arginine (R) at amino acid position 423 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
not provided Uncertain:1
Reported in an individual with developmental delay and hypotonia in published literature (Kartvelishvili et al., 2017); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Also known as R387Q due to alternative nomenclature; This variant is associated with the following publications: (PMID: 28419689) -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at